Newsroom

Sorted by: Latest

-

ASC25 Student Supercomputer Challenge: Shanghai Jiao Tong University Crowned Champion; Peking University Earns Silver

BEIJING--(BUSINESS WIRE)--ASC25 Student Supercomputer Challenge: Shanghai Jiao Tong University Crowned Champion; Peking University Earns Silver...
-

OPPO Smiling Angel Program Honors Outstanding Frontline Staff Who Bring a Human Touch to the Tech Experience

SHENZHEN, China--(BUSINESS WIRE)--Global technology brand OPPO hosted the 2025 Smiling Angel Awards Ceremony in Shenzhen on April 28th, recognizing 163 frontline staff from customer service and retail teams for their exceptional performance. Driven by OPPO’s belief that technology is not an ends in itself but a means to serve people, the Smiling Angel initiative is the most important annual awards honoring frontline staff who exemplify OPPO’s commitment to creating human-centric technology and...
-

OPPO Smiling Angel Program Honors Outstanding Frontline Staff Who Bring a Human Touch to the Tech Experience

SHENZHEN, China--(BUSINESS WIRE)--Global technology brand OPPO hosted the 2025 Smiling Angel Awards Ceremony in Shenzhen on April 28th, recognizing 163 outstanding frontline staff from customer service and retail teams for their exceptional performance. Driven by OPPO’s belief that technology is not an ends in itself but a means to serve people, the Smiling Angel initiative is the most important annual awards honoring frontline staff who exemplify OPPO’s commitment to creating human-centric tec...
-

ひびき・パース・アドバイザーズは株式会社巴コーポレーションの2025年6月27日開催予定の第93回定時株主総会に向けて株主提案を実施しました

東京--(BUSINESS WIRE)--(ビジネスワイヤ) -- ひびき・パース・アドバイザーズ(以下、「私ども」または「ひびき」といいます。)と投資一任契約を締結しているひびき・パース・アオバ・ファンド(以下、「HPAF」といいます。)は、株式会社巴コーポレーション(以下、「当社」といいます。)に対し、2025年6月27日開催予定の第93回定時株主総会に向けた株主提案(提案内容は以下2議案)を行いました。 当社の取締役(監査等委員である取締役及び社外取締役を除く)に対する年額300百万円以内、付与上限を251,000株とする譲渡制限株式付与のための金銭報酬債権の付与 DOE10%に相当する剰余金の配当、来期以降も同額以上の配当額を維持することを目標とすること 当社は立体構造建築を得意とする建築業を営んでおり、特に1932年に開発した「ダイヤモンドトラス」の立体構造の技術は、美しい大空間の創造を可能にし、その高い技術力を背景に、無柱大張間建築のパイオニアとして建築業界において絶大な信頼と評価を受けています。 優れた事業を誇る当社ですが、以下のような課題を抱えていることから、①当社の...
-

Hibiki Path Advisors Submits Shareholder Proposals for Tomoe Corporation’s 93rd Annual General Meeting Scheduled for 27th June 2025

TOKYO--(BUSINESS WIRE)--Hibiki Path Aoba Fund (hereinafter referred to as “HPAF”), which has a discretionary investment contract with Hibiki Path Advisors (hereinafter referred to as “we”, “our” or “Hibiki”), have submitted two shareholder proposals to be voted on at Tomoe Corporation (hereinafter referred to as “Tomoe”)’s upcoming 93rd Annual General Meeting of Shareholders scheduled for 27th June 2025. The proposals are as follows: Granting restricted stock compensation—up to 300 million yen...
-

E2open Announces Acquisition by WiseTech Global, Concluding Strategic Review

DALLAS--(BUSINESS WIRE)--E2open Parent Holdings, Inc. (NYSE: ETWO) (“E2open” or the “Company”), the connected supply chain SaaS platform with a leading multi-enterprise network, today announced that it has entered into a definitive agreement to be acquired by WiseTech Global Limited (ASX: WTC) (“WiseTech”), a leading provider of logistics execution software solutions. The acquisition marks the conclusion of e2open’s previously announced strategic review process. Under the terms of the transacti...
-

FGIC Announces TSA Termination

NEW YORK--(BUSINESS WIRE)--Financial Guaranty Insurance Company (“FGIC”) announces today that it has terminated the Transaction Support Agreement dated as of February 29, 2024 (the “TSA”), among FGIC and certain holders of outstanding FGIC-insured securities and units issued by the Custodial Trusts holding Puerto Rico-related securities insured by FGIC, regarding a potential transaction that would have accelerated the run-off of FGIC’s insured portfolio in accordance with the terms of the TSA....
-

ベイジーン、ASCO 2025で先駆的ながん研究を発表―血液腫瘍および固形腫瘍治療の新たな定義づけへ

カリフォルニア州サンカルロス--(BUSINESS WIRE)--(ビジネスワイヤ) -- ベイジーン(NASDAQ:ONC、HKEX:06160、SSE:688235、BeOne Medicines Ltd.へ社名変更予定)は、グローバルなオンコロジー企業です。当社は、2025年5月30日から6月3日に米国イリノイ州シカゴで開催される米国臨床腫瘍学会(ASCO)年次総会において、血液腫瘍および固形腫瘍ポートフォリオ全体にわたる新たなデータを特徴とする23件の演題を発表します。そのうち2件は口頭発表に選定されています。これらのデータは、がんに対し多角的に取り組み、革新的な医薬品をできる限り多くの患者に世界中で届けるという当社のビジョンを反映しています。 「ASCOはがん医療の進歩を示すうえで非常に重要な場であり、世界中のより多くの患者の治療成績向上という私たちのミッションを反映した23件の演題を発表できることを誇りに思います」と、ベイジーンの固形腫瘍領域チーフ・メディカル・オフィサーであるマーク・ラナサ医学博士は述べています。「今年の発表内容は、CLLにおけるBRUKINSAの長期追...
-

FLOC Investors Have Opportunity to Join Flowco Holdings Fraud Investigation with the Schall Law Firm

LOS ANGELES--(BUSINESS WIRE)--FLOC Investors Have Opportunity to Join Flowco Holdings Fraud Investigation with the Schall Law Firm...
-

FLGT Investors Have Opportunity to Join Fulgent Genetics, Inc. Fraud Investigation with the Schall Law Firm

LOS ANGELES--(BUSINESS WIRE)--FLGT Investors Have Opportunity to Join Fulgent Genetics, Inc. Fraud Investigation with the Schall Law Firm...